Assessing Zoetis (NYSE:ZTS) Valuation As Higher Value Pet Treatments Offset Softer Vet Visits

Simply Wall St.06:11

AdvertisementConference spotlight and shifting demand in animal health Zoetis (ZTS) is set to present at the 2026 KeyBanc Capital Markets Healthcare Virtual Forum on March 17, as investors assess how ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622011688?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/215548781-main-header/1756213611450","is_english":true,"pubTime":"2026-03-25 06:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622011688","market":"hk","top_or_hot":-1,"title":"Assessing Zoetis (NYSE:ZTS) Valuation As Higher Value Pet Treatments Offset Softer Vet Visits","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementConference spotlight and shifting demand in animal health Zoetis (ZTS) is set to present at the 2026 KeyBanc Capital Markets Healthcare Virtual Forum on March 17, as investors assess how ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/assessing-zoetis-nysezts-valuation-as-higher-value-pet-treat\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Zoetis (NYSE:ZTS) Valuation As Higher Value Pet Treatments Offset Softer Vet Visits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Zoetis (NYSE:ZTS) Valuation As Higher Value Pet Treatments Offset Softer Vet Visits\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-25 06:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/assessing-zoetis-nysezts-valuation-as-higher-value-pet-treat><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementConference spotlight and shifting demand in animal health Zoetis (ZTS) is set to present at the 2026 KeyBanc Capital Markets Healthcare Virtual Forum on March 17, as investors assess how ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/assessing-zoetis-nysezts-valuation-as-higher-value-pet-treat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0158827781.USD","symbol_name":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/assessing-zoetis-nysezts-valuation-as-higher-value-pet-treat","article_id":"2622011688","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/215548781-main-header/1756213611450"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/assessing-zoetis-nysezts-valuation-as-higher-value-pet-treat","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622011688","pubTimestamp":1774390268,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Conference spotlight and shifting demand in animal health\nZoetis (ZTS) is set to present at the 2026 KeyBanc Capital Markets Healthcare Virtual Forum on March 17, as investors assess how softer routine vet visits and higher-value treatments are shaping the animal health business.\nSee our latest analysis for Zoetis.\nDespite resilient demand for higher-value treatments, Zoetis shares have been under pressure, with a 30 day share price return of 9.98% and a 1 year total shareholder return of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","BK4007":"制药","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0079474960.USD":"联博美国增长基金A","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","ZTS":"Zoetis Inc.","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0058720904.USD":"联博国际健康护理基金A","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0385154629.USD":"贝莱德营养科学基金A2","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","NYSE":"纽交所","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","BK4588":"碎股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2308191902.HKD":"BNP PARIBAS ECOSYSTEM RESTORATION \"CLASSIC\" (HKD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC"},"translate_title":"评估硕腾（纽约证券交易所股票代码：ZTS）的估值，因为更高价值的宠物治疗抵消了较软的兽医就诊","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NYSE":1.5,"ZTS":1.5},"content_text":"AdvertisementConference spotlight and shifting demand in animal health Zoetis (ZTS) is set to present at the 2026 KeyBanc Capital Markets Healthcare Virtual Forum on March 17, as investors assess how softer routine vet visits and higher-value treatments are shaping the animal health business. See our latest analysis for Zoetis. Despite resilient demand for higher-value treatments, Zoetis shares have been under pressure, with a 30 day share price return of 9.98% and a 1 year total shareholder return of 27.08%, suggesting momentum has been fading even as the business adapts to changing pet care spending. If you are comparing Zoetis with opportunities in health related technology, this could be a good moment to scan the market through 36 healthcare AI stocks With Zoetis shares down on a 1 year view despite revenue and net income growth, and trading below some valuation estimates, you need to ask: is this weakness a chance to enter, or is the market already pricing in future growth? Most Popular Narrative: 23.2% Undervalued Zoetis closed at $115.93, while the most followed narrative pegs fair value at $151.00 using a 6.98% discount rate, framing a sizeable valuation gap for investors to assess.  Significant growth potential is driven by unmet demand, market innovation, and leadership in key animal health segments, supporting recurring revenue and strong brand power. Expansion into emerging international markets and alternative sales channels diversifies revenue streams and sustains above-market growth while ongoing cost discipline improves margins.  Read the complete narrative. Curious what kind of revenue profile and margin path could support that fair value, and what earnings multiple is built into the story? The narrative ties together growth, profitability and required returns in a way that might surprise you. Result: Fair Value of $151.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are clear watchpoints, including execution risk around new osteoarthritis launches and growing competition in key franchises that could challenge the premium multiple story. Find out about the key risks to this Zoetis narrative. Next Steps Mixed about what the market is signaling here? Take a moment to review the data, weigh both the concerns and the upside, and evaluate it in relation to 5 key rewards and 1 important warning sign. Ready for more investment ideas? If you stop with just one company, you risk missing opportunities that better fit your goals, so use the screener to line up your next few ideas confidently.  Target potential mispricings by scanning companies that look out of favor but have quality traits through the 59 high quality undervalued stocks. Prioritize resilience by focusing on businesses with sturdy finances using the solid balance sheet and fundamentals stocks screener (39 results). Hunt for under-the-radar stories that the wider market may be overlooking with the screener containing 25 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zoetis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622011688","isCrawlerRequest":true}